Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sisram Medical Ltd. ( (HK:1696) ) has issued an update.
Sisram Medical Ltd. announced a Commercial Distribution Co-operation Agreement with Fosun Wanbang (Jiangsu) to enhance the distribution of DAXXIFY® in Mainland China. This agreement aligns with Sisram’s business model, allowing the company to leverage its sublicense rights to improve its market position and generate additional revenue. The collaboration aims to streamline the supply chain, ensuring product safety and quality, while enhancing market efficiency.
The most recent analyst rating on (HK:1696) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sisram Medical Ltd. stock, see the HK:1696 Stock Forecast page.
More about Sisram Medical Ltd.
Sisram Medical Ltd., incorporated in Israel, operates in the medical industry, focusing on the commercialization and marketing of medical products. The company is involved in the distribution of botulinum toxin type A for injection, known as DAXXIFY®, primarily targeting the aesthetics market in Mainland China.
Average Trading Volume: 1,985,085
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.73B
For an in-depth examination of 1696 stock, go to TipRanks’ Overview page.